Gapping up
In reaction to strong earnings/guidance: SILC +7.8%, PHG +2.8%, S +2.8%, POST +1.8%, RYAAY +1.6%, DHR+0.8%, PETS +0.8%, .
M&A news:
In reaction to strong earnings/guidance: SILC +7.8%, PHG +2.8%, S +2.8%, POST +1.8%, RYAAY +1.6%, DHR+0.8%, PETS +0.8%, .
M&A news:
- TERP +6.2% (Brookfield Asset Management (BAM) enters letter agreement with Appaloosa LP forming a group that holds 34.4% active stake; parties intend to enter into agreement to act as joint bidders for the potential purchase of SunEdison's (SUNEQ) shares of TERP)
- SCTY +2.1% (SolarCity, Tesla (TSLA) making progress towards signing a definitive merger agreement, according to Reuters)
- CKEC +2.1% (announces amended merger with AMC Theatres (AMC), stockholders will have the option to elect to receive either $33.06/share in cash or 1.0819 shares of AMC's Class A common stock)
- PBR +0.9% (signs sale and purchase agreement with the Southern Cross Group for 100% of Petrobras Chile), .
Other news:
- BLPH +43.8% (announces approval to commence Phase 2 trial for INOpulse to treat pulmonary hypertension in chronic obstructive pulmonary disease)
- BIND +37.3% (announces there are two bidders in addition to Pfizer's (PFE) initial stalking horse bid of ~$20 mln in auction for its assets)
- GNVC +33.3% (notified by its collaborator, Novartis (NVS), that the FDA has lifted the clinical hold on the Phase 1/2 clinical trial of CGF166 in patients with severe to profound hearing loss)
- GLNG +10% (Golar LNG and Schlumberger (SLB) announce creation of OneLNG a joint venture to rapidly develop low cost gas reserves to LNG)
- CLSN +8.3% (announces data from the immunotherapy study of newly diagnosed ovarian cancer patients)
- AVXL +6.7% (presents 31-week safety data from Phase 2a Study of ANAVEX 2-73)
- MU +4.7% (declares dividend of one right for each share of common stock outstanding at the close of business on August 1)
- MACK +4.5% (Shire and Merrimack confirm positive CHMP opinion for ONIVYDE showing that combined with chemotherapysignificantly increased overall survival)
- ALDR +2.5% (announces top-line 24-week data demonstrating persistent migraine prevention in a Phase 2b clinical trial evaluating ALD403)
- ERIC +2.2% (CEO steps down; CFO to assume the CEO position; initiates search for new CEO)
- CLNT +2% (continued strength)
Analyst comments:
- OCLR +3.8% (upgraded to Strong Buy from Buy at Needham)
- PHM +2.1% (upgraded to Buy from Hold at Deutsche Bank)
- HPE +2% (upgraded to Buy from Neutral at Citigroup)
- WFM +1.8% (upgraded to Outperform from Neutral at Macquarie)
- VMW +1.4% (resumed with a Overweight at Morgan Stanley)
- MDLZ +1.1% (upgraded to Positive from Neutral at Susquehanna)